Abstract 141P
Background
Patients with unresectable upper GI cancers have limited therapies and a dismal prognosis. While granting access to additional treatments, enrollment in phase I trials offers unclear benefits in this population.
Methods
Individual patient data of subjects with advanced upper GI cancers receiving ≥1 dose of the study drug within phase I trials at SCRI UK between 2011-2023 were collected. Objective response rate (ORR: CR+PR), clinical benefit rate (CBR: % with any tumor shrinkage), and disease control rate (DCR: CR+PR+SD) were assessed by RECIST v1.1, and progression-free survival (PFS) and overall survival (OS) from trial start. Outcomes were reported using descriptive statistics and uni- and multivariate analyses. Subjects participating in more than one trial (n=20) were assessed separately in each study.
Results
Of 1796 patients screened, 104 patients with upper GI cancers (65% esophageal/junctional; 35% gastric) from 35 phase I trials were included. Most were male (75%), had adenocarcinoma (91%), and stage IV at diagnosis (73%). At trial entry, median age was 61 (range 20-86), median number of prior lines 2 (range 1-4), and median number of metastatic sites 2 (range 1-5). Seventy-four (60%), 37 (30%), and 13 (10%) received immunotherapy (IO), small molecules, or antibody-drug conjugates, respectively; 27 (22%) received a molecularly matched therapy. Median follow-up was 14.8 months (95% CI, 10.39-68.15). ORR was 17% (95% CI, 0.10-0.26), CBR 43% (95% CI, 0.33-0.53), and DCR 87% (95% CI, 0.79-0.93) across all trials. Efficacy was comparable by number of prior lines, trial drugs, or allocation to matched therapy. In response-evaluable patients across all trials (n=100), median OS and PFS were 12.3 (95% CI, 7.77-16.88) and 2.9 months (95% CI, 2.45-3.40), respectively, and were significantly longer for responders versus non-responders (both p<0.001). Depth of response, low metastatic burden (≤2 sites), and IO combos remained significant predictors of improved survival in multivariate analysis.
Conclusions
Participation in phase I trials offers substantial benefits in refractory upper GI cancers regardless of biomarker selection with compelling results in late-line settings and potential early access to newly approved therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract